VRTX
Vertex Pharmaceuticals
NASDAQ: VRTX · Boston, MA · Healthcare
$546.12-11.84 (-2.12%)Closed
Market Cap$112.00B
Cash$13.80Bmost recent
Runwayprofitable
P/E (TTM)29.5EPS $14.72
52-Wk Range$376.62 – $557.96
Avg Volume1.4M3-month
Healthstrong

Commercial-stage biotech with a dominant cystic fibrosis franchise, expanding into pain, T1D, and sickle cell via Casgevy.

Price & Trading Activity

Daily close with catalyst overlays and trading volume

$546.12+16.6%
Pipeline

Drug candidates sponsored by Vertex Pharmaceuticals · ClinicalTrials.gov

49 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4LUM/IVA
Cystic Fibrosis
Completed
2023-08-22past
5
Phase 4Suzetrigine
Acute Pain+2 more
Recruiting
2027-01-25
7
Phase 2VX-509
Rheumatoid Arthritis+1 more
Completed
2014-07past
3
Phase 3Lumacaftor
Cystic Fibrosis
Completed
2015-10past
3
Phase 3Lumacaftor Plus Ivacaftor Combination
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation+1 more
Completed
2016-04past
2
Phase 3VX-661/Ivacaftor
Cystic Fibrosis
Completed
2017-02past
1
Phase 3Ivacaftor
Cystic Fibrosis
Completed
2017-09past
5
Phase 3Tezacaftor/Ivacaftor
Cystic Fibrosis
Completed
2018-08-09past
3
Phase 2VX-210
Cervical Spinal Cord Injury
Terminated
2018-11past
1
Phase 3VX-445/TEZ/IVA
Cystic Fibrosis
Completed
2018-12-28past
1
Phase 3VX-659/TEZ/IVA
Cystic Fibrosis
Completed
2020-09-09past
3
Phase 3VX-121/TEZ/D-IVA
Cystic Fibrosis
Active, not recruiting
2026-10-30
4
Phase 3ELX/TEZ/IVA
Cystic Fibrosis
Active, not recruiting
2027-04-06
11
Phase 3CTX001
Sickle Cell Disease+9 more
Recruiting
2027-06-06
3
Phase 2Povetacicept
Primary Membranous Nephropathy
Recruiting
2028-12-29
1
Phase 3Exa-cel
Sickle Cell Disease
Withdrawn
2033-12-31
1
Phase 2biricodar dicitrate
Lung Cancer
Terminated
2001-02past
1
Phase 2Ribavirin
Chronic Hepatitis C
Completed
2008-05past
1
Phase 2AVN944
Pancreatic Cancer+1 more
Terminated
2010-03past
2
Phase 2Telaprevir
Hepatitis C+1 more
Completed
2011-04past
4
Phase 2telaprevir or matching placebo
Hepatitis C+1 more
Completed
2012-03past
1
Phase 1VCH-222 or matching placebo
Hepatitis C
Completed
2012-09past
1
Phase 2VX-787
Influenza Virus
Completed
2012-10past
1
Phase 2VX-222
Chronic Hepatitis C Virus
Completed
2013-09past
1
Phase 2VX-135
Chronic Hepatitis C+3 more
Completed
2014-05past
1
Phase 1Placebo (matched to VX-121 suspension)
Cystic Fibrosis
Completed
2019-05-03past
1
Phase 2VX-121
Cystic Fibrosis
Completed
2019-12-10past
1
Phase 2VX-864
Alpha1-Antitrypsin Deficiency
Completed
2021-05-04past
1
Phase 2Inaxaplin
Proteinuric Kidney Disease
Completed
2026-07-20past
1
Phase 1VX-670
Myotonic Dystrophy Type 1 (DM1)
Active, not recruiting
2027-02-02
1
Phase 1VX-264
Type 1 Diabetes
Active, not recruiting
2027-03-12
1
Phase 2VX-407
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Active, not recruiting
2027-07-22
3
Phase 2Merimepodib
Hepatitis C+1 more
Completed—1
Phase 1VX-770
Cystic Fibrosis+1 more
Completed
2010-12past
3
Phase 1VX-809
Cystic Fibrosis
Completed
2011-05past
1
Phase 1Placebo
Pain
Completed
2022-09-14past
1
Phase 1VX-708
Acute Pain
Completed
2023-04-14past
1
Phase 1VX-634
Alpha 1-Antitrypsin Deficiency
Completed
2023-05-24past
1
Phase 1Vanzacaftor
Cystic Fibrosis
Completed
2023-06-14past
1
Phase 1VX-668
Alpha-1 Antitrypsin Deficiency
Completed
2023-09-12past
1
Phase 1VX-548
Pain
Completed
2024-03-30past
4
Phase 1VX-118
Cystic Fibrosis
Completed
2024-05-04past
1
Phase 1IXP
Focal Segmental Glomerulosclerosis (FSGS)
Completed
2024-12-20past
1
Phase 1VX-993
Pain
Completed
2025-02-18past
3
Phase 1VX-973
Pain
Completed
2025-07-21past
1
Phase 1VX-828
Cystic Fibrosis
Completed
2026-07-10past
1
Phase 1VX-581
Cystic Fibrosis
Recruiting
2026-11-19
1
Phase 1AVN-944 capsules for oral administration
Acute Leukemia+5 more
Completed—1
N/AUnnamed
Cystic Fibrosis
Completed
2019-12past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.